Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Keros Therapeutics (KROS) Other Operating Expenses (2019 - 2020)

Keros Therapeutics filings provide 2 years of Other Operating Expenses readings, the most recent being -$1.5 million for Q1 2020.

  • On a quarterly basis, Other Operating Expenses fell 146.69% to -$1.5 million in Q1 2020 year-over-year; TTM through Dec 2020 was -$1.5 million, a 41.89% increase, with the full-year FY2020 number at -$1.5 million, up 41.89% from a year prior.
  • Other Operating Expenses hit -$1.5 million in Q1 2020 for Keros Therapeutics, down from -$78000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of -$78000.0 in Q4 2019 to a low of -$1.5 million in Q1 2020.